Precision medicine for advanced colorectal and gastroesophageal cancer

被引：0

作者：

Miguel Reyes, Jose ^{[1
]}

机构：

[1] Clin Las Condes, Ctr Canc Maria Luisa Solari Falabella, Dept Oncol Med, Santiago, Chile

来源：

REVISTA MEDICA CLINICA LAS CONDES | 2022年 / 33卷 / 02期

关键词：

Esophageal Cancers; Gastric Cancer; Neoplasma; KRAS WILD-TYPE; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-III; FLUOROURACIL FAILURE; CONTINUOUS-INFUSION; 2ND-LINE TREATMENT; PLUS CHEMOTHERAPY; RANDOMIZED-TRIAL; GASTRIC-CANCER;

D O I：

10.1016/j.rmclc.2022.03.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Colorectal and gastroesophageal cancer have a global high incidence and a high mortality rate. Surgery persists as the only curative therapy for patients with early stages of both diseases. In those patients that are diagnosed with metastatic or unresectable cancer, or that become metastatic after locoregional treatment, chemotherapy has been the traditional therapy, with rather poor results in terms of survival or progression free survival. Precision medicine using molecular markers is changing this situation. Herein we review the most relevant aspects with regards to advances in the treatment of both diseases.

引用

页码：125 / 139

页数：15

共 90 条

[71] Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring [J].

Seligmann, Jenny F. ;

Fisher, David J. ;

Brown, Louise C. ;

Adams, Richard A. ;

Graham, Janet ;

Quirke, Philip ;

Richman, Susan D. ;

Butler, Rachel ;

Domingo, Enric ;

Blake, Andrew ;

Yates, Emma ;

Braun, Michael ;

Collinson, Fiona ;

Jones, Rob ;

Brown, Ewan ;

de Winton, Emma ;

Humphrey, Timothy C. ;

Parmar, Mahesh ;

Kaplan, Richard ;

Wilson, Richard H. ;

Seymour, Matthew ;

Maughan, Timothy S. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (33) :3705-+

[72] Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial [J].

Seymour, Matthew T. ;

Brown, Sarah R. ;

Middleton, Gary ;

Maughan, Timothy ;

Richman, Susan ;

Gwyther, Stephen ;

Lowe, Catherine ;

Seligmann, Jennifer F. ;

Wadsley, Jonathan ;

Maisey, Nick ;

Chau, Ian ;

Hill, Mark ;

Dawson, Lesley ;

Falk, Stephen ;

O'Callaghan, Ann ;

Benstead, Kim ;

Chambers, Philip ;

Oliver, Alfred ;

Marshall, Helen ;

Napp, Vicky ;

Quirke, Phil .

LANCET ONCOLOGY, 2013, 14 (08) :749-759

[73] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer [J].

Shitara, Kohei ;

Bang, Yung-Jue ;

Iwasa, Satoru ;

Sugimoto, Naotoshi ;

Ryu, Min-Hee ;

Sakai, Daisuke ;

Chung, Hyun-Cheol ;

Kawakami, Hisato ;

Yabusaki, Hiroshi ;

Lee, Jeeyun ;

Saito, Kaku ;

Kawaguchi, Yoshinori ;

Kamio, Takahiro ;

Kojima, Akihito ;

Sugihara, Masahiro ;

Yamaguchi, Kensei .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) :2419-2430

[74] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) [J].

Siena, S. ;

Raghav, K. ;

Masuishi, T. ;

Yamaguchi, K. ;

Nishina, T. ;

Elez, E. ;

Rodriguez, J. ;

Chau, I. ;

Di Bartolomeo, M. ;

Kawakami, H. ;

Suto, F. ;

Kobayashi, K. ;

Koga, M. ;

Inaki, K. ;

Kuwahara, Y. ;

Takehara, I. ;

Grothey, A. ;

Yoshino, T. .

ANNALS OF ONCOLOGY, 2021, 32 :S532-S532

[75] Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial [J].

Siena, Salvatore ;

Di Bartolomeo, Maria ;

Raghav, Kanwal ;

Masuishi, Toshiki ;

Loupakis, Fotios ;

Kawakami, Hisato ;

Yamaguchi, Kensei ;

Nishina, Tomohiro ;

Fakih, Marwan ;

Elez, Elena ;

Rodriguez, Javier ;

Ciardiello, Fortunato ;

Komatsu, Yoshito ;

Esaki, Taito ;

Chung, Ki ;

Wainberg, Zev ;

Sartore-Bianchi, Andrea ;

Saxena, Kapil ;

Yamamoto, Eriko ;

Bako, Emarjola ;

Okuda, Yasuyuki ;

Shahidi, Javad ;

Grothey, Axel ;

Yoshino, Takayuki .

LANCET ONCOLOGY, 2021, 22 (06) :779-789

[76] Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy [J].

Smyth, E. C. ;

Gambardella, V ;

Cervantes, A. ;

Fleitas, T. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :590-599

[77] Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study [J].

Sun, Jong-Mu ;

Shen, Lin ;

Shah, Manish A. ;

Enzinger, Peter ;

Adenis, Antoine ;

Doi, Toshihiko ;

Kojima, Takashi ;

Metges, Jean-Philippe ;

Li, Zhigang ;

Kim, Sung-Bae ;

Cho, Byoung Chul ;

Mansoor, Wasat ;

Li, Shau-Hsuan ;

Sunpaweravong, Patrapim ;

Maqueda, Maria Alsina ;

Goekkurt, Eray ;

Hara, Hiroki ;

Antunes, Luis ;

Fountzilas, Christos ;

Tsuji, Akihito ;

Oliden, Victor Castro ;

Liu, Qi ;

Shah, Sukrut ;

Bhagia, Pooja ;

Kato, Ken .

LANCET, 2021, 398 (10302) :759-771

[78] Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study [J].

Tabernero, Josep ;

Hoff, Paulo M. ;

Shen, Lin ;

Ohtsu, Atsushi ;

Shah, Manish A. ;

Cheng, Karen ;

Song, Chunyan ;

Wu, Haiyan ;

Eng-Wong, Jennifer ;

Kim, Katherine ;

Kong, Yoon-Koo .

LANCET ONCOLOGY, 2018, 19 (10) :1372-1384

[79] Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study [J].

Thuss-Patience, Peter C. ;

Shah, Manish A. ;

Ohtsu, Atsushi ;

Van Cutsem, Eric ;

Ajani, Jaffer A. ;

Castro, Hugo ;

Mansoor, Wasat ;

Chung, Hyun Cheol ;

Bodoky, Gyorgy ;

Shitara, Kohei ;

Phillips, Gail D. Lewis ;

van der Horst, Tina ;

Harle-Yge, Marie-Laurence ;

Althaus, Betsy L. ;

Kang, Yoon-Koo .

LANCET ONCOLOGY, 2017, 18 (05) :640-653

[80] Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy [J].

Topalian, Suzanne L. ;

Drake, Charles G. ;

Pardoll, Drew M. .

CANCER CELL, 2015, 27 (04) :450-461

← 1 2 3 4 5 6 7 8 9 →